Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Critical Evaluation of Current Concepts and Moving to New Horizons in the Management of IBDAxel Dignass
United European Gastroenterology Journal|August 19, 2016
UEG Standards and Guidelines: A UEG initiative to reduce health inequalities across EuropeAxel Dignass
Current Drug Targets|September 4, 2014
Complementary therapies in inflammatory bowel diseasesPhilip Esters, Axel Dignass
Zeitschrift Fur Gastroenterologie|August 11, 2023
Torsten Kucharzik, Axel Dignass
United European Gastroenterology Journal|November 3, 2018
Young GI angle: How to find and read guidelines?Grainne Holleran, Axel Dignass
Gastroenterology|January 6, 2005
Mesalamine in the treatment of active Crohn's diseaseAxel Dignass, P Marteau
United European Gastroenterology Journal|December 6, 2021
Join the myUEG community and become an official myUEG Associate for freeAxel Dignass, Helena Cortez-Pinto
Expert Review of Hematology|January 29, 2021
Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemiaAysegül Aksan, Axel Dignass, Jürgen Stein
Expert Opinion on Pharmacotherapy|March 21, 2024
Upadacitinib in Crohn's diseaseAxel Dignass, Philip Esters, Cathrin Flauaus
Advances in Therapy|June 3, 2019
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in DenmarkAyşegül Aksan, Axel Dignass, Jürgen Stein
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Critical Evaluation of Current Concepts and Moving to New Horizons in the Management of IBDAxel Dignass
United European Gastroenterology Journal|August 19, 2016
UEG Standards and Guidelines: A UEG initiative to reduce health inequalities across EuropeAxel Dignass
Current Drug Targets|September 4, 2014
Complementary therapies in inflammatory bowel diseasesPhilip Esters, Axel Dignass
Zeitschrift Fur Gastroenterologie|August 11, 2023
Torsten Kucharzik, Axel Dignass
United European Gastroenterology Journal|November 3, 2018
Young GI angle: How to find and read guidelines?Grainne Holleran, Axel Dignass
Gastroenterology|January 6, 2005
Mesalamine in the treatment of active Crohn's diseaseAxel Dignass, P Marteau
United European Gastroenterology Journal|December 6, 2021
Join the myUEG community and become an official myUEG Associate for freeAxel Dignass, Helena Cortez-Pinto
Expert Review of Hematology|January 29, 2021
Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemiaAysegül Aksan, Axel Dignass, Jürgen Stein
Expert Opinion on Pharmacotherapy|March 21, 2024
Upadacitinib in Crohn's diseaseAxel Dignass, Philip Esters, Cathrin Flauaus
Advances in Therapy|June 3, 2019
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in DenmarkAyşegül Aksan, Axel Dignass, Jürgen Stein
Pageof 18